Related references
Note: Only part of the references are listed.Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis
Fausto Petrelli et al.
BREAST (2023)
Cancer statistics, 2023
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2023)
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022
Nina Ditsch et al.
BREAST CARE (2022)
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial
Lucia Del Mastro et al.
LANCET ONCOLOGY (2022)
Risk-based decision-making in the treatment of HER2-positive early breast cancer: Recommendations based on the current state of knowledge
Christian Jackisch et al.
CANCER TREATMENT REVIEWS (2021)
Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106)
Pierre Kerbrat et al.
EUROPEAN JOURNAL OF CANCER (2017)
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
N. Harbeck et al.
EUROPEAN JOURNAL OF CANCER (2013)
Fluorouracil, Doxorubicin, and Cyclophosphamide (FAC) Versus FAC Followed by Weekly Paclitaxel As Adjuvant Therapy for High-Risk, Node-Negative Breast Cancer: Results From the GEICAM/2003-02 Study
Miguel Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University)
H. Sakr et al.
MEDICAL ONCOLOGY (2013)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Extended Benefit from Sequential Administration of Docetaxel after Standard Fluorouracil, Epirubicin, and Cyclophosphamide Regimen for Node-Positive Breast Cancer: The 8-Year Follow-Up Results of the UNICANCER-PACS01 Trial
Bruno Coudert et al.
ONCOLOGIST (2012)
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 x FEC versus 3 x FEC/3 x Docetaxel
Eva J. Kantelhardt et al.
BMC CANCER (2011)
Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
Manfred Schmitt et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2011)
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.
Miguel Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-025EFcomparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial
M. Schmidt et al.
ANNALS OF ONCOLOGY (2009)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
Clifford A. Hudis et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients:: The FNCLCC PACS 01 trial
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer:: 10-year follow-up results of The French Adjuvant Study Group 05 randomized trial
J Bonneterre et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination
N Harbeck et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients
MP Look et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1
F Jänicke et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Share Paper
